The Klein Law Firm announces the commencement of an investigation of Antares Pharma, Inc. (NASDAQ: ATRS) concerning possible violations of federal securities laws.

On October 11, 2017, the Company received a letter from the U.S. Food and Drug Administration stating that the agency had "identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments" for its product candidate Xyosted.

Then on October 20, 2017, Antares announced receipt of a Complete Response Letter from the FDA regarding the New Drug Application for Xyosted. The Company stated that the FDA could not approve the NDA in its present form due to concerns that Xyosted "could cause a clinically meaningful increase in blood pressure" and also noted the FDA's concerns "regarding the occurrence of depression and suicidality."

If you suffered a loss in Antares and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/ATRS-Info-Request-Form-216.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171030006052/en/

Copyright Business Wire 2010